SavedAdd your journal

Journals / Türkiye Fiziksel Tıp ve Rehabilitasyon Dergisi / 2014 / Cilt: 60 - Sayı: 1

Guillain-Barre Syndrome Associated with Peginterferon Alfa-2a: A Case Report

Peginterferon Alfa-2a ile İlişkili Guillain-Barre Sendromu

Ercan MADENCİ
İrfan KOCA
Mehmet UÇAR
Ahmet ÇELİK
Özlem ALTINDAĞ
Pages
65–68
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In this article, a 58-year-old woman with the clinical findings of Guillain-Barre syndrome in the sixth week of PEG-IFa-2a treatment is analyzed and discussed.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Polyethylene glycol-interferon ? (PEG-IFN?), used in the treatment of chronic hepatitis C, has the potential risk for serious side effects.
📊
Key Findings & Data:Among the most frequent side effects are symptoms similar to flu, depression, nervousness, and bone marrow suppression.
💡
Conclusion & Impact:In this article, a 58-year-old woman with the clinical findings of Guillain-Barre syndrome in the sixth week of PEG-IFa-2a treatment is analyzed and discussed.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Polyethylene glycol-interferon ? (PEG-IFN?), used in the treatment of chronic hepatitis C, has the potential risk for serious side effects. Among the most frequent side effects are symptoms similar to flu, depression, nervousness, and bone marrow suppression. Serious neurological side effects that have an influence on the peripheral nerves are rarely reported. In this article, a 58-year-old woman with the clinical findings of Guillain-Barre syndrome in the sixth week of PEG-IFa-2a treatment is analyzed and discussed.

Özet

Kronik hepatit C tedavisinde yaygın olarak kullanılan Polietilen glikolinterferon ? (PEG-IFN?)'nın önemli yan etki potansiyeli mevcuttur. Grip benzeri semptomlar, depresyon, sinirlilik ve kemik iliği supresyonu en sık ortaya çıkan yan etkilerdir. Periferal sinirleri etkileyen önemli nörolojik yan etkiler nadiren bildirilmiştir. Bu yazıda, PEG-IFa-2a tedavisinin 6. haftasında Guillain-Barre Sendromu klinik bulgularıyla başvuran 58 yaşında kadın hasta anlatıldı ve tartışıldı.

🔖

Cite This Article

MADENCİ, E., KOCA, İ., UÇAR, M., ÇELİK, A., ALTINDAĞ, Ö. (2022). Guillain-Barre Syndrome Associated with Peginterferon Alfa-2a: A Case Report. Türkiye Fiziksel Tıp ve Rehabilitasyon Dergisi, Cilt: 60 - Sayı: 1, 65–68. https://ajindex.com/articles/628830

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (2)

  1. Ropper AH. The Guillain-Barre syndrome. N Engl J Med 1992;326:1130-6. [CrossRef] Anta Funes JA, Mariona Mastero VA, Helano Carranza E. Guil- lain Barre Syndrome - etiology and pathogenesis. Rev Invest Clin 2002;54:357-63.
  2. Ghany MG, Strader DB, Thomas DL, Seeff LB. American Associa- tion for the study of liver diseases. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009;49:1335-74. [CrossRef] Niazi MA, Azhar A, Tufail K, Feyssa EL, Penny SF, McGregory M, et al. Guillain-Barre syndrome associated with peginterferon alfa-2a for chronic hepatitis C: A case report. WJ Hepatology 2010;2:162-6. [CrossRef] Khiani V, Kelly T, Shibli A, Jensen D, Mohanty SR. Acute inflamma- tory demyelinating polyneuropathy associated with pegylated in- terferon alpha 2a therapy for chronic hepatitis C virus infection. World J Gastroenterol 2008;14:318-21. [CrossRef] Ogawara K, Kuwabara S, Mori M, Hattori T, Koga M, Yuki N. Axonal Guillain-Barré syndrome: relation to antiganglioside anti- bodies and Campylobacter jejuni infection in Japan. Ann Neurol 2000;48:624-31. [CrossRef] Haber P, DeStefano F, Angulo FJ, Iskander J, Shadomy SV, Weintraub E, Chen RT. Guillain-Barré syndrome following influenza vaccina- tion. JAMA 2004;292:2478-81. [CrossRef] Gordon PH, Wilbourn AJ. Early electrodiagnostic findings in Guil- lain-Barré syndrome. Arch Neurol 2001;58:913-7. [CrossRef] Hughes RA, Wijdicks EF, Barohn R, Benson E, Cornblath DR, Hahn AF, et al. Practice parameter: immunotherapy for Guillain-Barré syndrome: re- port of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2003;61:736-40. [CrossRef] Meythalen JM, Devivo MJ, Braswell WC. Rehabilitation outcomes of patients who have developed Guillain-Barre syndrome. Am J Phys Med Rehabil 1997;76:411-9. [CrossRef] Hiraga A, Mori M, Ogawara K, Kojima S, Kanesaka T, Misawa S, et al. Recovery patterns and long term prognosis for axonal Guillain- Barré syndrome. J Neurol Neurosurg Psychiatry 2005;76:719-22. [CrossRef]